This article is more than 5 years old. Information may no longer be current.
DS Biopharma receives European patent for potential fatty liver drug
Click Here to Manage Email Alerts
DS Biopharma announced it has been granted a patent by the European Patent Office for its fatty liver drug candidate, DS102, also known as 15-HEPE, for the treatment of fatty liver disorders.
According to a press release, the patent titled “Compositions Comprising 15-HEPE and Methods of Using the Same,” covers the use of DS102 in the treatment of fatty liver disorders NAFLD and NASH and provides exclusivity to DS Biopharma through 2033.
“We are delighted to announce this important milestone in our advanced program to develop an effective treatment for fatty liver diseases using an innovative bioactive lipid,” Tien Nghiem, director of product development and intellectual property at DS Biopharma, said in the release.
A phase 1 trial investigating DS102 for the treatment of fatty liver disorders is in the process of being completed, according to the release, and a phase 2 trial is expected to begin in early 2016.
Disclosures: Nghiem is employed by DS Biopharma.